» Articles » PMID: 16681555

Metabolic Syndrome--a New World-wide Definition. A Consensus Statement from the International Diabetes Federation

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2006 May 10
PMID 16681555
Citations 2211
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To establish a unified working diagnostic tool for the metabolic syndrome (MetS) that is convenient to use in clinical practice and that can be used world-wide so that data from different countries can be compared. An additional aim was to highlight areas where more research into the MetS is needed.

Participants: The International Diabetes Federation (IDF) convened a workshop held 12-14 May 2004 in London, UK. The 21 participants included experts in the fields of diabetes, public health, epidemiology, lipidology, genetics, metabolism, nutrition and cardiology. There were participants from each of the five continents as well as from the World Health Organization (WHO) and the National Cholesterol Education Program-Third Adult Treatment Panel (ATP III). The workshop was sponsored by an educational grant from AstraZeneca Pharmaceuticals.

Consensus Process: The consensus statement emerged following detailed discussions at the IDF workshop. After the workshop, a writing group produced a consensus statement which was reviewed and approved by all participants.

Conclusions: The IDF has produced a new set of criteria for use both epidemiologically and in clinical practice world-wide with the aim of identifying people with the MetS to clarify the nature of the syndrome and to focus therapeutic strategies to reduce the long-term risk of cardiovascular disease. Guidance is included on how to compensate for differences in waist circumference and in regional adipose tissue distribution between different populations. The IDF has also produced recommendations for additional criteria that should be included when studying the MetS for research purposes. Finally, the IDF has identified areas where more studies are currently needed; these include research into the aetiology of the syndrome.

Citing Articles

Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy.

Owczarek A, Musialik J, Stefanski A, Mossakowska M, Zieba K, Wiecek A Front Med (Lausanne). 2025; 12:1445973.

PMID: 40066165 PMC: 11891235. DOI: 10.3389/fmed.2025.1445973.


Effect and factors associated with weight and waist circumference reductions in information and communication technology-based specific health guidance.

Iwayama Y, Shimba Y, Viswanathan C, Yano Y Environ Occup Health Pract. 2025; 5(1).

PMID: 40059931 PMC: 11841796. DOI: 10.1539/eohp.2023-0001-OA.


Caveolin Gene, a Possible Risk Factor for Metabolic Syndrome in Humans: A Systematic Review and Meta-Analysis.

Arefian M, Mazaheri-Tehrani S, Yazdi M, Kelishadi R Int J Prev Med. 2025; 16:7.

PMID: 40046695 PMC: 11878647. DOI: 10.4103/ijpvm.ijpvm_216_24.


Prevalence of Metabolic Syndrome Among Adults Aged 50 and Above and Associated Factors: A Cross-Sectional Study From Ardakan Cohort Study on Aging (ACSA).

Hooshmand E, Akbarzade I, Delbari D, Niroomand M, Ghavidel F, Saatchi M Health Sci Rep. 2025; 8(3):e70508.

PMID: 40046099 PMC: 11879886. DOI: 10.1002/hsr2.70508.


Association between mean platelet volume and adiponectin in patients with metabolic syndrome.

Marinkovic M, Nesic J, Petrovic I, Jovanovic I, Sekulic M, Djukic S J Appl Biomed. 2025; 22(4):208-213.

PMID: 40033808 DOI: 10.32725/jab.2024.022.